The transcription factor, MEF2C, mediates a change in approximately one half of the expressed frontal cortical transcriptome controlling cellular metabolism and synaptic strength in response to acute loss of sleep.
Inclusion of a neuroligin alternatively spliced insert that interacts with a neurexin glycan modification promote development of functional synaptic connections between neurons and may help alleviate consequences of NLGN mutations.
High-throughput phenotypic screening followed by unbiased target identification reveals a new molecular glue HQ461 that induces CDK12-DDB1 interaction to promote degradation of Cyclin K via the ubiquitin proteasome system.
GABA-A receptors on dopamine neuron axons not only depolarize the membrane but also limit action potential propagation, an effect potentiated by positive allosteric modulators of GABA-A receptors like diazepam (Valium).
One α-synuclein strain inhibited proteasome activity and induced apparent pathologies, while the other did not, indicating a strain-dependent toxicity of α-synuclein aggregates, which support a prion-like behavior of α-synuclein.
Operant drug self-administration in a mouse model of neuropathic pain reveals pain-relieving effects of a cannabinoid CB2 receptor agonist that are mediated through CB2 receptors of neurons and lymphocytes.